NEW YORK (GenomeWeb) – Diagnostics firm Applied Proteomics is shifting is business strategy to rely more heavily on deals with outside partners to commercialize its protein-based tests.

The company has determined that "it may not be in our best interest to stand up our own sales force," said CEO Premal Shah, noting that API plans moving forward to focus its resources on test and assay development as opposed to test commercialization.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.